Kala Pharmaceuticals, Inc. – Trademark Portfolio
Entity Type: 03
Kala Pharmaceuticals, Inc. holds 25 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 24 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 10 trademarks are registered. Notable registered marks include V, KALA, EYSUVIS, AMPPLIFY, and INVELTYS. The owner is based in Watertown, MA.
490 Arsenal Way, Suite 120
Watertown, MA 02472
Showing of trademarks Trademarks
Trademark Classifications
Kala Pharmaceuticals, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Kala Pharmaceuticals, Inc. have?
Kala Pharmaceuticals, Inc. has 25 U.S. trademarks filed with the USPTO. Of these, 10 registered, 14 abandoned, 1 cancelled.
What trademark classes does Kala Pharmaceuticals, Inc. file in?
Kala Pharmaceuticals, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Kala Pharmaceuticals, Inc.'s most well-known trademarks?
Kala Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as V, KALA, EYSUVIS, AMPPLIFY, and INVELTYS. These are among 10 currently registered trademarks in the portfolio.
What is Kala Pharmaceuticals, Inc.'s trademark registration success rate?
Kala Pharmaceuticals, Inc. has a 40% trademark registration rate, with 10 out of 25 resolved applications resulting in successful registration. Currently, 0 applications are pending review.